AOD-9604Check methods and identity
What the LAT8881 neuropathic pain crossover study measured
2 numbered sourcesSource years 2019, 2021
Peptides are short amino-acid chains connected by peptide bonds. They can serve as biological signals or as laboratory tools for probing how those signals work. AOD-9604 is a 16-amino-acid growth hormone derivative that was later studied under the name LAT8881. An older randomized human study tested whether people with neuropathic pain reported a different level of pain while receiving LAT8881 than while receiving placebo. [1, 2]
The trial used a crossover design. People took part in two periods, one with active treatment and one with placebo, with assignment determining the order. This design lets researchers compare outcomes within the same person, which is helpful because pain scores often differ substantially between individuals. The analysis still needs to account for changes over time and for the order in which the treatments were given. [1]
The main outcome used a numeric scale from zero to ten. The registry reports an estimated treatment difference of −0.14 points, with a confidence interval running from −0.76 to 0.49. That interval includes both a reduction and an increase, and the analysis did not show a statistically significant difference. The study’s size and the spread of plausible effects also matter when interpreting the result. [1]
The registry contains results from a defined group and a specified comparison. It lets readers distinguish an observed estimate from the objective written before the trial began. It does not settle every question about LanCL1 signaling or pain after different kinds of nerve injury. It does provide the relevant human comparison for the conditions studied, and that comparison did not establish a benefit on the primary pain outcome. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
